The studies by Dahlén et al. [30] and Ringheanu et al. [31] revealed that the incubation of immune cells isolated from IBD patients with anti-TNF-α antibodies (infliximab) reduced the expression and secretion of proinflammatory cytokines, including IL-6 and IL-13. This evidence concerns the gene IL13 and inflammatory bowel disease.